<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00243386</url>
  </required_header>
  <id_info>
    <org_study_id>060201</org_study_id>
    <nct_id>NCT00243386</nct_id>
  </id_info>
  <brief_title>Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A</brief_title>
  <official_title>Advate Antihemophilic Factor (Recombinant), Plasma/Albumin Free Method (ADVATE rAHF-PFM): A Phase 4 Study Comparing Two Prophylactic Regimens in Subjects With Severe or Moderately Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxalta now part of Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this randomized, two-arm parallel clinical study in 66 previously
      treated patients with severe or moderately severe hemophilia A is to compare the rate of
      bleeding episodes for standard prophylaxis (20-40 IU/kg every 48 ± 6 hours; actual dose
      determined by the investigator) with that of alternate prophylaxis (20-80 IU/kg every 72 + 6
      hours; actual dose determined by Baxter utilizing an algorithm and the patient's
      pharmacokinetic data). The rates of bleeding episodes for the on-demand regimen and the
      prophylaxis regimens will also be compared for the cross-over portion of the study. Enrolled
      patients will be treated originally on demand for a period of 6 months and then they will be
      randomized into one of the prophylaxis arms. Prophylactic treatment will last for a period of
      12 months +/- 2 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens</measure>
    <time_frame>12 months ±2 weeks</time_frame>
    <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2):
Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator)
PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor)
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens</measure>
    <time_frame>12 months ±2 weeks</time_frame>
    <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):
Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens</measure>
    <time_frame>On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)</time_frame>
    <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR).
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens</measure>
    <time_frame>On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)</time_frame>
    <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR)
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens</measure>
    <time_frame>On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)</time_frame>
    <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X' = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR).
Any Prophylaxis = Standard or PK-Driven Prophylaxis
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm</measure>
    <time_frame>12 months ±2 weeks</time_frame>
    <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):
Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding Episodes Treated With 1 to ≥4 Infusions</measure>
    <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
    <description>The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Hemostasis for Treatment of Bleeding Episodes</measure>
    <time_frame>On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)</time_frame>
    <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~8 hrs after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Area Under the Curve (AUC)</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C-max)</measure>
    <time_frame>Within 1 hour post-infusion</time_frame>
    <description>Maximal Factor VIII Concentration After Infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjusted Incremental Recovery (IR)</measure>
    <time_frame>30 minutes pre-infusion to 48 hours post-infusion</time_frame>
    <description>Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.
Adjusted IR defined as:
[Cmax (IU/dL) - pre-infusion FVIII (IU/dL)]/dose (IU/kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight-Adjusted Clearance</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as the weight-adjusted dose divided by total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution at Steady State</measure>
    <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
    <description>Computed as weight-adjusted clearance * mean residence time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factor VIII Inhibitor Development</measure>
    <time_frame>Throughout study period (4 years and 5 months)</time_frame>
    <description>Number of treated participants who developed factor VIII inhibitors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With AEs Related to Investigational Product (IP)</measure>
    <time_frame>Throughout study period (4 years and 5 months)</time_frame>
    <description>Number of treated participants with AEs judged to be possibly or probably related to treatment with IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)</measure>
    <time_frame>Throughout study period (4 years and 5 months)</time_frame>
    <description>Number of treated participants with 1 or more AE regardless of relatedness to IP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen</measure>
    <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen</measure>
    <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness</measure>
    <time_frame>Throughout study period (4 years and 5 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen</measure>
    <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
    <description>This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS</measure>
    <time_frame>Baseline</time_frame>
    <description>Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens</measure>
    <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
    <description>Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period</measure>
    <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
    <description>Differences in health domain scores = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS).
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period</measure>
    <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
    <description>Change = (End of on-demand treatment) - (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period</measure>
    <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
    <description>Change = (End of on-demand treatment) - (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PK-driven prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free</intervention_name>
    <description>Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antihemophilic factor, recombinant, manufactured protein-free</intervention_name>
    <description>PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has severe or moderately severe hemophilia A as defined by a baseline
             factor VIII level &lt;= 2% of normal, as tested at screening

          -  The subject has a documented history of at least 150 exposure days to factor VIII
             concentrates (either plasma-derived or recombinant)

          -  The subject is within 7 to 65 years of age

          -  The subject has a Karnofsky performance score &gt; (greater than) 60

          -  The subject is human immunodeficiency virus negative (HIV-) or is HIV+ with a CD4
             count &gt;= 400 cells/mm³ (CD4 count determined at screening, if necessary)

          -  The subject has been on a documented on-demand treatment regimen for at least 12
             months immediately prior to enrollment

          -  The subject has a documented history (e.g. in medical charts or dispensing
             information, or signed investigator statement) of at least 8 joint hemorrhages in the
             12 months immediately prior to enrollment

          -  The subject resides within the coverage area of the mobile compliance device; coverage
             area will be determined at screening

          -  The subject or the subject's legally authorized representative has provided written
             informed consent

        Exclusion Criteria:

          -  The subject has a known hypersensitivity to factor VIII concentrates or mouse or
             hamster proteins

          -  The subject has a history of factor VIII inhibitors with a titer &gt;= 0.6 BU (by
             Bethesda or Nijmegen assay) at any time prior to screening

          -  The subject has a detectable factor VIII inhibitor at screening, with a titer &gt;= 0.4
             BU (by Nijmegen Assay) in the central laboratory

          -  The subject has severe chronic liver disease as evidenced by, but not limited to, any
             of the following: International Normalized Ratio (INR) &gt; 1.4, hypoalbuminemia, portal
             vein hypertension including presence of otherwise unexplained splenomegaly and history
             of esophageal varices.

          -  The subject has been diagnosed with an inherited or acquired hemostatic defect other
             than hemophilia A (e.g., qualitative platelet defect or von Willebrand's Disease)

          -  The subject has been treated during the last sixty (60) days prior to or is being
             treated at screening/enrollment with an immunomodulating drug.

          -  The subject has participated in another investigational study within thirty (30) days
             of enrollment

          -  The subject has previously participated in a clinical study with rAHF-PFM

          -  The subject's clinical condition may require a major surgery (defined as moderate to
             critical risk and perioperative blood loss ≥ 500 mL) during the period of the
             subject's participation in the study

          -  The subject is female of childbearing potential with a positive pregnancy test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Collins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiff and Vale NHS</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szombathely</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florence</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ljubljana</city>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Czechia</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Slovenia</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2005</study_first_submitted>
  <study_first_submitted_qc>October 21, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2005</study_first_posted>
  <results_first_submitted>March 14, 2012</results_first_submitted>
  <results_first_submitted_qc>October 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2012</results_first_posted>
  <disposition_first_submitted>June 27, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 27, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 29, 2011</disposition_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 21 European and 9 United States clinical sites beginning January 2006 and completing in June 2010</recruitment_details>
      <pre_assignment_details>82 participants were enrolled and screened. 7 were screen failures, 1 was withdrawn for non-compliance, and 1 requested withdrawal. Therefore, 73 of the 82 enrolled were exposed to investigational product in the first part of the study (on-demand treatment).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Participants first underwent an open-label pharmacokinetic (PK) evaluation of rAHF-PFM. 48 hours after the initial PK study, a 6 month period of on-demand treatment was conducted (Part 1). After completing the on-demand treatment, participants were randomized to 1 of 2 prophylactic regimens for 12 months ±2 weeks (Part 2). The standard prophylactic regimen was dosed at 20 to 40 IU/kg every 48 ±6 hours, and the PK-driven prophylaxis regimen was dosed at 20 to 80 IU/kg every 72 ±6 hours.</description>
        </group>
        <group group_id="P2">
          <title>PK-Driven Prophylaxis</title>
          <description>The PK-driven prophylaxis regimen was dosed at 20 to 80 IU/kg of rAHF-PFM every 72 ±6 hours</description>
        </group>
        <group group_id="P3">
          <title>Standard Prophylaxis</title>
          <description>The standard prophylactic regimen was dosed at 20 to 40 IU/kg of rAHF-PFM every 48 ±6 hours</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>On-Demand Regimen (Study Part 1)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="0">Participants were randomized to PK-Driven or Standard Prophylaxis after Part 1 (On-Demand Regimen)</participants>
                <participants group_id="P3" count="0">Participants were randomized to PK-Driven or Standard Prophylaxis after Part 1 (On-Demand Regimen)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screen Failures</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>End of Part 1, But Prior to Prophylaxis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="0">Participants were randomized to PK-Driven or Standard Prophylaxis after Part 1 (On-Demand Regimen)</participants>
                <participants group_id="P3" count="0">Participants were randomized to PK-Driven or Standard Prophylaxis after Part 1 (On-Demand Regimen)</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn for Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>PK-Driven or Standard Prophylaxis</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Participants were randomized to PK-Driven or Standard Prophylaxis after Part 1 (On-Demand Regimen)</participants>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawn for Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants first underwent an open-label evaluation of rAHF-PFM PK. 48 hours after the initial PK study, a 6 month period of on-demand treatment was conducted (Part 1). After completing the on-demand treatment, participants were randomized to 1 of 2 prophylactic regimens for 12 months ±2 weeks (Part 2). The standard prophylactic regimen was dosed at 20 to 40 IU/kg every 48 ±6 hours, and the PK-driven prophylaxis regimen was dosed at 20 to 80 IU/kg every 72 ±6 hours.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" lower_limit="7" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens</title>
        <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2):
Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator)
PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor)
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.</description>
        <time_frame>12 months ±2 weeks</time_frame>
        <population>Per Protocol</population>
        <group_list>
          <group group_id="O1">
            <title>PK-Driven Prophylaxis</title>
            <description>PK-driven prophylaxis regimen dosed at 20 to 80 IU/kg every 72 ±6 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>Standard prophylaxis regimen dosed at 20 to 40 IU/kg every 48 ±6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Transformed Annualized Bleed Rate Estimates From Each of the 1-year Prophylaxis Regimens</title>
          <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Study Part 2):
Standard prophylaxis (20-40 IU/kg (every 48 ±6 hour), exact regimen determined by investigator)
PK-driven prophylaxis (20-80 IU/kg (every 72 ±6 hour), exact regimen determined by sponsor)
Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X = bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the t-test.</description>
          <population>Per Protocol</population>
          <units>(bleeds/year)^(1/2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.61" spread="1.10"/>
                    <measurement group_id="O2" value="1.46" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A t-test was used to compare the means of the transformed data. The null-hypothesis tested was H0: X'A(PK-driven prophylaxis) - X'B (standard prophylaxis) = 0 (i.e., no difference for treatment under the 2 prophylactic regimens.
X' = (ABR+0.5)^(1/2)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6016</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens</title>
        <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR).
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
        <time_frame>On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Versus Standard Prophylaxis</title>
            <description>On-demand: rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, Gastrointestinal (GI), and intracranial (60-100 IU/kg every 8-12 hours)
Standard Prophylaxis: 20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Standard Prophylaxis Treatment Regimens</title>
          <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Standard Prophylaxis Treatment TABR).
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
          <population>Intent to treat</population>
          <units>(bleeds/year)^(1/2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>2-sided paired T-tests were done comparing transformed annualized bleeding rates between On-Demand and Prophylaxis regimens.</p_value_desc>
            <method>Paired t-Test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens</title>
        <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR)
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
        <time_frame>On-demand 6 months (± 2 weeks); followed by Prophylaxis 12 months (± 2 weeks)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Versus PK-Driven Prophylaxis</title>
            <description>On-demand: rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours)
PK-driven prophylaxis: 20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and PK-Driven Prophylaxis Treatment Regimens</title>
          <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (PK-Driven Prophylaxis Treatment TABR)
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
          <population>Intent to treat</population>
          <units>(bleeds/year)^(1/2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" spread="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>2-sided paired T-tests were done comparing transformed annualized bleeding rates between On-Demand and Prophylaxis regimens.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens</title>
        <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR).
Any Prophylaxis = Standard or PK-Driven Prophylaxis
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
        <time_frame>On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Versus Any Prophylaxis</title>
            <description>On-demand: rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours)
Prophylaxis:
Standard prophylaxis: 20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator
PK-driven prophylaxis: 20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Difference of Transformed Annualized Bleeding Rate Between On-Demand and Any Prophylaxis Treatment Regimens</title>
          <description>Annualized bleed rates were transformed using the square root of the number of bleeding episodes observed (X bleeds/year), X′ = √(X + 0.5). This transformation was performed to stabilize the variance and align the sample distribution with the assumption of normality inherent in using the paired t-test.
Mean Difference of Transformed Annualized Bleeding Rate (TABR) = (On-Demand Treatment TABR) - (Any Prophylaxis Treatment TABR).
Any Prophylaxis = Standard or PK-Driven Prophylaxis
Participants from the On-Demand portion of the study were subsequently randomized to either Standard Prophylaxis or PK-Driven Prophylaxis, (i.e the same participants were analyzed across the two measurement time periods).</description>
          <population>Intent to treat</population>
          <units>(bleeds/year)^(1/2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.14" spread="1.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>2-sided paired T-tests were done comparing transformed annualized bleeding rates between On-Demand and Prophylaxis regimens.</p_value_desc>
            <method>Paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm</title>
        <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):
Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.</description>
        <time_frame>12 months ±2 weeks</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PK-Driven Prophylaxis</title>
            <description>PK-driven prophylaxis regimen dosed at 20 to 80 IU/kg every 72 ±6 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>Standard prophylaxis regimen dosed at 20 to 40 IU/kg every 48 ±6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Total Weight-Adjusted Dose of rAHF-PFM Used Per Year for Each Prophylaxis Arm</title>
          <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):
Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.</description>
          <population>Intent to treat</population>
          <units>IU/kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5197.8" lower_limit="3268.4" upper_limit="8273.5"/>
                    <measurement group_id="O2" value="5768.2" lower_limit="4728.0" upper_limit="6425.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4924</p_value>
            <method>Wilcoxon-Rank Sum (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Episodes Treated With 1 to ≥4 Infusions</title>
        <description>The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis</description>
        <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
        <population>Intent to Treat Efficacy Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Treatment</title>
            <description>rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours)</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis Treatment</title>
            <description>20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
          <group group_id="O3">
            <title>PK-Driven Prophylaxis</title>
            <description>20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Episodes Treated With 1 to ≥4 Infusions</title>
          <description>The number of bleeding episodes treated with 1, 2, 3, or ≥4 infusions of rAHF-PFM to achieve adequate hemostasis</description>
          <population>Intent to Treat Efficacy Set</population>
          <units>Bleeding episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 infusion (n = 62, 13, 22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1168"/>
                    <measurement group_id="O2" value="68"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 infusions (n = 51, 6, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 infusions (n = 27, 2, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 or more infusions (n = 21, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Hemostasis for Treatment of Bleeding Episodes</title>
        <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~8 hrs after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
        <time_frame>On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)</time_frame>
        <population>Hemostatic Efficacy Rating Analysis Set (Participants with bleeding episodes that were rated)</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Regimen</title>
            <description>rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours)</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
          <group group_id="O3">
            <title>PK-Driven Prophylaxis</title>
            <description>20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Hemostasis for Treatment of Bleeding Episodes</title>
          <description>Number of rAHF-PFM-treated bleeding episodes with an assessment of hemostasis (4-point ordinal scale):
Excellent: Full pain relief &amp; bleeding cessation within ~8 hrs of 1 infusion. Additional infusions may have been given to maintain hemostasis;
Good: Definite pain relief and/or improvement in bleeding within ~8 hrs after infusion. Possibly requires &gt;1 infusion for complete resolution;
Fair: Probable or slight relief of pain &amp; slight improvement in bleeding within
~8 hrs after infusion. Requires &gt;1 infusion for complete resolution;
None: No improvement or condition worsens</description>
          <population>Hemostatic Efficacy Rating Analysis Set (Participants with bleeding episodes that were rated)</population>
          <units>bleeding episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Excellent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="943"/>
                    <measurement group_id="O2" value="38"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fair</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Area Under the Curve (AUC)</title>
        <description>Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Total Area Under the Curve (AUC)</title>
          <description>Total AUC estimated by AUC 0-48h plus an area extrapolated from the log-linear regression model</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1334.45" spread="454.33"/>
                    <measurement group_id="O2" value="1061.26" spread="452.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve</title>
        <description>Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve</title>
          <description>Area under the factor VIII (FVIII) plasma concentration versus time curve (AUC) from 0 to 48 hours estimated using the linear trapezoidal method</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>IU*h/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1213.98" spread="323.96"/>
                    <measurement group_id="O2" value="966.68" spread="330.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (C-max)</title>
        <description>Maximal Factor VIII Concentration After Infusion</description>
        <time_frame>Within 1 hour post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (C-max)</title>
          <description>Maximal Factor VIII Concentration After Infusion</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>IU/dL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.12" spread="20.15"/>
                    <measurement group_id="O2" value="74.47" spread="11.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Incremental Recovery (IR)</title>
        <description>Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.
Adjusted IR defined as:
[Cmax (IU/dL) – pre-infusion FVIII (IU/dL)]/dose (IU/kg)</description>
        <time_frame>30 minutes pre-infusion to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Incremental Recovery (IR)</title>
          <description>Change in factor VIII concentration from pre- to post-infusion at initial and termination study visits.
Adjusted IR defined as:
[Cmax (IU/dL) – pre-infusion FVIII (IU/dL)]/dose (IU/kg)</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>IU/dL per IU/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.81" spread="0.41"/>
                    <measurement group_id="O2" value="1.47" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life</title>
        <description>Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life</title>
          <description>Computed from the regression slope in the terminal phase of the model. Terminal half life is the time it takes for the plasma concentration or the amount of drug in the body to be reduced by 50%.</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.91" spread="5.07"/>
                    <measurement group_id="O2" value="14.66" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight-Adjusted Clearance</title>
        <description>Computed as the weight-adjusted dose divided by total AUC</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Weight-Adjusted Clearance</title>
          <description>Computed as the weight-adjusted dose divided by total AUC</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>mL/(kg*h)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.89" spread="1.21"/>
                    <measurement group_id="O2" value="5.17" spread="1.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time</title>
        <description>Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time</title>
          <description>Computed as total Area Under the Moment Curve (AUMC) divided by the total AUC</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.71" spread="7.16"/>
                    <measurement group_id="O2" value="17.88" spread="5.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution at Steady State</title>
        <description>Computed as weight-adjusted clearance * mean residence time</description>
        <time_frame>Pharmacokinetic evaluations: 30 minutes pre-infusion up to 48 hours post-infusion</time_frame>
        <population>Intent to Treat Pharmacokinetic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
          </group>
          <group group_id="O2">
            <title>&lt;14 Years of Age</title>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution at Steady State</title>
          <description>Computed as weight-adjusted clearance * mean residence time</description>
          <population>Intent to Treat Pharmacokinetic Analysis Set</population>
          <units>dL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.65" spread="0.19"/>
                    <measurement group_id="O2" value="0.84" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factor VIII Inhibitor Development</title>
        <description>Number of treated participants who developed factor VIII inhibitors</description>
        <time_frame>Throughout study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All participants who were exposed to Investigational Product (IP)</description>
          </group>
        </group_list>
        <measure>
          <title>Factor VIII Inhibitor Development</title>
          <description>Number of treated participants who developed factor VIII inhibitors</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With AEs Related to Investigational Product (IP)</title>
        <description>Number of treated participants with AEs judged to be possibly or probably related to treatment with IP</description>
        <time_frame>Throughout study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All participants who were exposed to IP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With AEs Related to Investigational Product (IP)</title>
          <description>Number of treated participants with AEs judged to be possibly or probably related to treatment with IP</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)</title>
        <description>Number of treated participants with 1 or more AE regardless of relatedness to IP</description>
        <time_frame>Throughout study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All participants who were exposed to IP</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported ≥1 AE Regardless of Relatedness to Investigational Product (IP)</title>
          <description>Number of treated participants with 1 or more AE regardless of relatedness to IP</description>
          <population>Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen</title>
        <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand</title>
            <description>rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours)</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
          <group group_id="O3">
            <title>PK-Driven Prophylaxis</title>
            <description>20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported ≥1 AE Regardless of Relatedness to IP by Treatment Regimen</title>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen</title>
        <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand</title>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
          <group group_id="O3">
            <title>PK-Driven Prophylaxis</title>
            <description>20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
          <group group_id="O4">
            <title>SAEs Outside of the 3 Treatment Arms</title>
            <description>Participants with SAEs that occurred after exposure to investigational product, but outside of the three treatment arms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With SAEs by Preferred MedDRA Term and Treatment Regimen</title>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ABDOMINAL PAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAUSEA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TOOTH ABSCESS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JOINT DISLOCATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAEMOPHILIC ARTHROPATHY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SYNOVITIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CALCULUS URINARY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HOSPITALIZATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PULPITIS DENTAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOMNAMBULISM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FACTOR VIII INHIBITION (UNCONFIRMED)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APPENDICITIS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PAIN IN EXTREMITY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness</title>
        <time_frame>Throughout study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>All Study Participants</title>
            <description>All participants who were exposed to investigational product (IP)</description>
          </group>
        </group_list>
        <measure>
          <title>AEs With Onset ≤1 Hour Following the End of an Infusion, Regardless of Relatedness</title>
          <population>Safety Analysis Set</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen</title>
        <description>This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs</description>
        <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand</title>
            <description>rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
          <group group_id="O3">
            <title>PK-Driven Prophylaxis</title>
            <description>20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe SAEs and Severe Non-SAEs by Preferred MedDRA Term and Treatment Regimen</title>
          <description>This outcome is focused only on SEVERE SAEs and SEVERE non-SAEs</description>
          <population>Safety Analysis Set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TOOTH ABSCESS (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAEMOPHILIC ARTHROPATHY (SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HAEMOPHILIC ARTHROPATHY (non-SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ABDOMINAL PAIN (non-SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ARTHRALGIA (non-SAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS</title>
        <description>Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>Baseline</time_frame>
        <population>Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Assessed Before Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>Baseline Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS</title>
          <description>Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Safety Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.56" lower_limit="17.29" upper_limit="57.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Physical (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.10" lower_limit="27.95" upper_limit="56.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.48" lower_limit="25.07" upper_limit="62.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.87" lower_limit="19.52" upper_limit="64.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.42" lower_limit="25.39" upper_limit="67.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.28" lower_limit="19.14" upper_limit="57.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role-Emotional (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.34" lower_limit="23.74" upper_limit="55.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.44" lower_limit="20.91" upper_limit="64.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.32" lower_limit="20.10" upper_limit="67.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.65" lower_limit="22.56" upper_limit="68.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens</title>
        <description>Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
        <population>Pharmacoeconomic Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Treatment</title>
            <description>rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator</description>
          </group>
          <group group_id="O3">
            <title>PK-Driven Prophylaxis</title>
            <description>20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
          <group group_id="O4">
            <title>Any Prophylaxis Treatment</title>
            <description>Any Prophylaxis Treatment (either Standard Prophylaxis or PK-Driven Prophylaxis) Standard Prophylaxis: 20-40 IU/kg (every 48 ± 6 hours), exact regimen to be determined by the investigator PK-Driven Prophylaxis: 20-80 IU/kg (every 72 ± 6 hours), exact regimen to be determined by the sponsor</description>
          </group>
        </group_list>
        <measure>
          <title>Health-related Quality of Life (HRQoL) Scores: PF, RP, BP, GH, VT, SF, RE, MH, PCS, and MCS at the End of Treatment Regimens</title>
          <description>Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS). Baseline SF-36v1 Scores, where data available. Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Pharmacoeconomic Analysis Set</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.5" lower_limit="29.4" upper_limit="62.8"/>
                    <measurement group_id="O2" value="51.6" lower_limit="19.9" upper_limit="62.8"/>
                    <measurement group_id="O3" value="51.6" lower_limit="29.4" upper_limit="62.8"/>
                    <measurement group_id="O4" value="51.6" lower_limit="19.9" upper_limit="62.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.9" lower_limit="19.5" upper_limit="64.0"/>
                    <measurement group_id="O2" value="48.6" lower_limit="19.5" upper_limit="64.0"/>
                    <measurement group_id="O3" value="46.2" lower_limit="29.8" upper_limit="60.3"/>
                    <measurement group_id="O4" value="48.6" lower_limit="19.5" upper_limit="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS), On-Demand n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.9" lower_limit="22.8" upper_limit="69.9"/>
                    <measurement group_id="O2" value="56.1" lower_limit="13.3" upper_limit="69.6"/>
                    <measurement group_id="O3" value="54.5" lower_limit="11.4" upper_limit="62.5"/>
                    <measurement group_id="O4" value="55.0" lower_limit="11.4" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH), On-Demand n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6" lower_limit="14.1" upper_limit="64.1"/>
                    <measurement group_id="O2" value="50.4" lower_limit="20.9" upper_limit="64.1"/>
                    <measurement group_id="O3" value="52.7" lower_limit="7.3" upper_limit="64.1"/>
                    <measurement group_id="O4" value="50.4" lower_limit="7.3" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS), On-Demand n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="16.1" upper_limit="61.2"/>
                    <measurement group_id="O2" value="50.2" lower_limit="17.6" upper_limit="68.8"/>
                    <measurement group_id="O3" value="47.3" lower_limit="25.3" upper_limit="62.3"/>
                    <measurement group_id="O4" value="47.8" lower_limit="17.6" upper_limit="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Functioning (PF), On-Demand n=62</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8" lower_limit="17.3" upper_limit="57.1"/>
                    <measurement group_id="O2" value="46.7" lower_limit="21.5" upper_limit="57.1"/>
                    <measurement group_id="O3" value="46.7" lower_limit="17.3" upper_limit="57.1"/>
                    <measurement group_id="O4" value="46.7" lower_limit="17.3" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3" lower_limit="23.7" upper_limit="55.3"/>
                    <measurement group_id="O2" value="55.3" lower_limit="23.7" upper_limit="55.3"/>
                    <measurement group_id="O3" value="55.3" lower_limit="23.7" upper_limit="55.3"/>
                    <measurement group_id="O4" value="55.3" lower_limit="23.7" upper_limit="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="28.0" upper_limit="56.2"/>
                    <measurement group_id="O2" value="56.2" lower_limit="28.0" upper_limit="56.2"/>
                    <measurement group_id="O3" value="56.2" lower_limit="28.0" upper_limit="56.2"/>
                    <measurement group_id="O4" value="56.2" lower_limit="28.0" upper_limit="56.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.3" lower_limit="30.0" upper_limit="57.1"/>
                    <measurement group_id="O2" value="51.7" lower_limit="24.6" upper_limit="57.1"/>
                    <measurement group_id="O3" value="51.7" lower_limit="13.7" upper_limit="57.1"/>
                    <measurement group_id="O4" value="51.7" lower_limit="13.7" upper_limit="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.8" lower_limit="32.5" upper_limit="70.4"/>
                    <measurement group_id="O2" value="56.2" lower_limit="27.8" upper_limit="70.4"/>
                    <measurement group_id="O3" value="56.2" lower_limit="23.0" upper_limit="68.0"/>
                    <measurement group_id="O4" value="56.2" lower_limit="23.0" upper_limit="70.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period</title>
        <description>Differences in health domain scores = (End of on-demand treatment) – (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS).
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
        <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
        <population>Pharmacoeconomic Analysis Set ≥14 Years and Older</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand to Standard Prophylaxis</title>
          </group>
          <group group_id="O2">
            <title>On-Demand to PK-Driven Prophylaxis</title>
          </group>
          <group group_id="O3">
            <title>On-Demand to Any Prophylaxis Treatment</title>
          </group>
        </group_list>
        <measure>
          <title>HRQoL Scores Change From On-Demand Treatment Regimen Period Through Prophylaxis Period</title>
          <description>Differences in health domain scores = (End of on-demand treatment) – (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen
Physical Functioning (PF); Role Limitation Due to Physical Health (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role Limitation Due to Emotional Problems (RE); Mental Health (MH), Physical Component Score (PCS); Mental Component Score (MCS).
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores for each of the 8 HRQoL/SF-36 health domain scores.</description>
          <population>Pharmacoeconomic Analysis Set ≥14 Years and Older</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning (PF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-10.48" upper_limit="14.68"/>
                    <measurement group_id="O2" value="-2.10" lower_limit="-18.88" upper_limit="20.97"/>
                    <measurement group_id="O3" value="-2.10" lower_limit="-18.88" upper_limit="20.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Physical (RP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-28.29" upper_limit="21.21"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-28.29" upper_limit="28.29"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-28.29" upper_limit="28.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bodily Pain (BP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-29.55" upper_limit="17.55"/>
                    <measurement group_id="O2" value="-4.29" lower_limit="-25.27" upper_limit="13.28"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-29.55" upper_limit="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General Health (GH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.74" lower_limit="-29.55" upper_limit="17.55"/>
                    <measurement group_id="O2" value="-2.34" lower_limit="-21.07" upper_limit="18.73"/>
                    <measurement group_id="O3" value="-2.34" lower_limit="-20.13" upper_limit="17.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vitality (VT)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-9.47" upper_limit="23.67"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-16.57" upper_limit="30.77"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-16.57" upper_limit="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social Functioning (SF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-21.72" upper_limit="16.29"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-16.29" upper_limit="16.29"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-21.72" upper_limit="16.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Role Emotional (RE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-10.53" upper_limit="31.60"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-31.60" upper_limit="21.07"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-31.60" upper_limit="31.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Health (MH)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-13.63" upper_limit="15.90"/>
                    <measurement group_id="O2" value="-1.13" lower_limit="-40.90" upper_limit="34.08"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-40.90" upper_limit="34.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical Component Score (PCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.55" lower_limit="-20.22" upper_limit="8.69"/>
                    <measurement group_id="O2" value="-3.14" lower_limit="-16.78" upper_limit="19.70"/>
                    <measurement group_id="O3" value="-2.76" lower_limit="-20.22" upper_limit="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental Component Score (MCS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" lower_limit="-8.31" upper_limit="21.64"/>
                    <measurement group_id="O2" value="0.79" lower_limit="-35.25" upper_limit="24.56"/>
                    <measurement group_id="O3" value="1.30" lower_limit="-35.25" upper_limit="24.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens</title>
        <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):
Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.</description>
        <time_frame>12 months ±2 weeks</time_frame>
        <population>Intent to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PK-Driven Prophylaxis</title>
            <description>PK-driven prophylaxis regimen dosed at 20 to 80 IU/kg every 72 ±6 hours</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>Standard prophylaxis regimen dosed at 20 to 40 IU/kg every 48 ±6 hours</description>
          </group>
        </group_list>
        <measure>
          <title>Median Annualized Bleed Rate Estimates From Each of the 1 Year Prophylaxis Regimens</title>
          <description>Participants were Randomized to Receive 1 of the 2 Following Prophylaxis Regimens (Part 2 of the study):
Standard prophylaxis- infusions every 48 ±6 hours, dosed at 20 to 40 IU/kg.
PK-driven prophylaxis- infusions every 72 ±6 hours dosed at 20 to 80 IU/kg.</description>
          <population>Intent to treat</population>
          <units>Bleeds per year</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" lower_limit="0.00" upper_limit="17.06"/>
                    <measurement group_id="O2" value="1.00" lower_limit="0.00" upper_limit="25.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1467</p_value>
            <method>Wilcoxon-Rank Sum (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period</title>
        <description>Change = (End of on-demand treatment) – (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.</description>
        <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
        <population>Pharmacoeconomic analysis set for participants ≥14 years of age</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
            <description>After an on-demand treatment period, participants were randomized to 1 of 2 prophylactic regimens for 12 months. The standard prophylactic regimen was dosed at 20 to 40 IU/kg every 48 ±6 hours, and the PK-driven prophylaxis regimen was dosed at 20 to 80 IU/kg every 72 ±6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Bodily Pain HRQoL Scores Change From On-Demand Period Through Prophylaxis Period</title>
          <description>Change = (End of on-demand treatment) – (End of prophylaxis regimen). A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.</description>
          <population>Pharmacoeconomic analysis set for participants ≥14 years of age</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-29.55" upper_limit="17.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <p_value_desc>Due to multiple hypotheses testing results, adjusted alpha values are set to α*=0.005 (0.05/10). Adjustments take into account 10 hypotheses tests between On-Demand and any Prophylaxis. Statistically significant results are considered p-values &lt; α*</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period</title>
        <description>Change = (End of on-demand treatment) – (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.</description>
        <time_frame>End of on-demand treatment period (6 months) and at study termination (approximately 18 months)</time_frame>
        <population>Pharmacoeconomic analysis set for participants ≥14 years of age</population>
        <group_list>
          <group group_id="O1">
            <title>≥14 Years of Age</title>
            <description>After an on-demand treatment period, participants were randomized to 1 of 2 prophylactic regimens for 12 months. The standard prophylactic regimen was dosed at 20 to 40 IU/kg every 48 ±6 hours, and the PK-driven prophylaxis regimen was dosed at 20 to 80 IU/kg every 72 ±6 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Component Scores (PCS) HRQoL Scores Change From On-Demand Period Through Prophylaxis Period</title>
          <description>Change = (End of on-demand treatment) – (End of prophylaxis regimen) A negative value for the median difference equates to a larger domain score for the prophylaxis regimen.
Scores range 0-100, higher scores represent better health. There is no total overall score; scoring is done for subscores and summary scores. The raw data from the SF-36 items were transformed to norm based scores.</description>
          <population>Pharmacoeconomic analysis set for participants ≥14 years of age</population>
          <units>Scores on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.76" lower_limit="-20.22" upper_limit="19.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <p_value_desc>Due to multiple hypotheses testing results, adjusted alpha values are set to α*=0.005 (0.05/10). Adjustments take into account 10 hypotheses tests between On-Demand and any Prophylaxis. Statistically significant results are considered p-values &lt; α*</p_value_desc>
            <method>Wilcoxon signed-rank test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Median (IQR) Annualized Bleed Rates</title>
        <description>Bleed rates (number of bleeding episodes per subject) were annualized to account for the varying number of days a subject may have actually been on each regimen.</description>
        <time_frame>On-demand 6 months (± 2 weeks); Prophylaxis 12 months (± 2 weeks)</time_frame>
        <population>Per-Protocol Efficacy Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>On-Demand Regimen</title>
            <description>After the initial PK study, a 6 month period of on-demand treatment was conducted (Part 1)</description>
          </group>
          <group group_id="O2">
            <title>Standard Prophylaxis</title>
            <description>Dosed at 20 to 40 IU/kg every 48 ±6 hours for 12 months (Part 2)</description>
          </group>
          <group group_id="O3">
            <title>PK-driven Prophylaxis</title>
            <description>Dosed at 20 to 80 IU/kg every 72 ±6 hours for 12 months (Part 2)</description>
          </group>
          <group group_id="O4">
            <title>Any Prophylaxis</title>
            <description>Either Standard or PK-driven Prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Median (IQR) Annualized Bleed Rates</title>
          <description>Bleed rates (number of bleeding episodes per subject) were annualized to account for the varying number of days a subject may have actually been on each regimen.</description>
          <population>Per-Protocol Efficacy Analysis Set</population>
          <units>Bleeding episodes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.98" lower_limit="35.73" upper_limit="56.53"/>
                    <measurement group_id="O2" value="0.99" lower_limit="0.00" upper_limit="2.14"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.00" upper_limit="4.08"/>
                    <measurement group_id="O4" value="1.00" lower_limit="0.00" upper_limit="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon Signed-Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Throughout the study period (4 years and 5 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>On-Demand</title>
          <description>On-demand: rAHF-PFM was to be used for the treatment of bleeding episodes according to the severity and type of episode by the protocol-recommended dosing until the episode resolved: superficial (10-20 IU/kg every 12-14 hours), minor joint (20-40 IU/kg every 12-14 hours), deep muscle (30-60 IU/kg every 12-14 hours), major joint or life-threatening (60-100 IU/kg every 8-12 hours), genitourinary, GI, and intracranial (60-100 IU/kg every 8-12 hours)</description>
        </group>
        <group group_id="E2">
          <title>Standard Prophylaxis</title>
          <description>Standard prophylaxis regimen dosed at 20 to 40 IU/kg (every 48 ±6 hours), exact regimen to be determined by the investigator</description>
        </group>
        <group group_id="E3">
          <title>PK-Driven Prophylaxis</title>
          <description>PK-driven prophylaxis regimen dosed at 20 to 80 IU/kg (every 72 ±6 hours) exact regimen to be determined by the sponsor</description>
        </group>
        <group group_id="E4">
          <title>SAEs Outside of the 3 Treatment Arms</title>
          <description>Participants with SAEs that occurred after exposure to investigational product, but outside of the three treatment arms</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>FACTOR VIII INHIBITION</sub_title>
                <description>This event was unconfirmed and therefore did not meet protocol definition for a Factor VIII inhibitor.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>TOOTH ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PULPITIS DENTAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMOPHILIC ARTHROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>SYNOVITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SOMNAMBULISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>HOSPITALIZATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Baxter’s agreements with PIs may vary per requirements of the individual PI, but contain common elements. For this study, PIs are restricted from independently publishing results until the earlier of the primary multicenter publication or ≤2 years after study completion. Baxter requires a review of results communications (e.g., for confidential information) ≥60 days prior to submission or communication. Baxter may request an additional delay of ≤60 days (e.g., intellectual property protection)</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Wing-Yen Wong, MD, Global Sr Medical Dir Hemophilia</name_or_title>
      <organization>Baxter Healthcare Corporation</organization>
      <email>wing_yen_wong@baxter.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

